Southern Palladium Ltd Stock Price Today (NSE: SDL)
Fundamental Score
Southern Palladium Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Southern Palladium Ltd share price today is ₹32.28, up +2.02% on NSE/BSE as of 7 August 2026. Southern Palladium Ltd (SDL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹26.87 (Cr). The 52-week high for SDL share price is ₹51.49 and the 52-week low is ₹19.05. The company has a Return on Equity (ROE) of -41.49% and a debt-to-equity ratio of 0.48.
Southern Palladium Ltd Share Price Chart — NSE/BSE Historical Performance
Southern Palladium Ltd share price chart: -31.80% return over the past month. 52-week high ₹51.49, 52-week low ₹19.05.
Southern Palladium Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹32.29 | ₹32.29 | ₹32.28 | ₹32.28 | 4.00 (Cr) | |
| ₹31.66 | ₹31.66 | ₹28.66 | ₹31.64 | 626.00 (Cr) | |
| ₹33.32 | ₹33.32 | ₹30.16 | ₹30.16 | 1.03K (Cr) | |
| ₹28.72 | ₹31.74 | ₹28.72 | ₹31.74 | 11.58K (Cr) | |
| ₹32.46 | ₹33.40 | ₹30.23 | ₹30.23 | 1.82K (Cr) | |
| ₹31.82 | ₹35.16 | ₹31.82 | ₹31.82 | 1.64K (Cr) | |
| ₹33.52 | ₹34.11 | ₹33.49 | ₹33.49 | 1.41K (Cr) | |
| ₹35.25 | ₹35.25 | ₹35.25 | ₹35.25 | 0.00 (Cr) | |
| ₹35.25 | ₹35.25 | ₹35.25 | ₹35.25 | 0.00 (Cr) | |
| ₹37.47 | ₹37.47 | ₹35.25 | ₹35.25 | 3.00 (Cr) |
Southern Palladium Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹32.46 | ₹33.40 | ₹28.66 | ₹32.28 | -0.55% | |
| ₹51.00 | ₹51.49 | ₹31.82 | ₹31.82 | -37.61% | |
| ₹36.67 | ₹49.11 | ₹36.67 | ₹49.11 | +33.92% | |
| ₹36.67 | ₹36.67 | ₹36.67 | ₹36.67 | +0.00% | |
| ₹34.93 | ₹36.67 | ₹34.93 | ₹36.67 | +4.98% | |
| ₹34.93 | ₹34.93 | ₹34.93 | ₹34.93 | +0.00% | |
| ₹31.69 | ₹34.93 | ₹31.69 | ₹34.93 | +10.22% | |
| ₹33.43 | ₹33.43 | ₹31.69 | ₹31.69 | -5.20% | |
| ₹31.92 | ₹35.18 | ₹31.84 | ₹33.43 | +4.73% | |
| ₹24.10 | ₹32.09 | ₹21.76 | ₹30.40 | +26.14% | |
| ₹25.56 | ₹28.24 | ₹24.59 | ₹25.36 | -0.78% | |
| ₹21.30 | ₹29.72 | ₹21.20 | ₹26.90 | +26.29% |
AI Research Briefing
Powered by Gemini · 2026-04-10
Bengwenyama or bust: SDL's fate hinges on South African mining rights and PGM prices.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Southern Palladium (SDL) appointed Mark Humphery as Project Manager for the Bengwenyama Project. The final approval of the Bengwenyama mining right is pending.
CORE STORY (THE REAL GAME)
SDL is a PGM (platinum group metals) play hinged on the Bengwenyama project in South Africa's Bushveld Complex. The market narrative revolves around the successful development of this project and its potential to become a major PGM mine.
- Appointment of experienced project manager
- Advancement of Definitive Feasibility Study
- Pending mining right approval
- Successful DFS completion
- Granting of mining right
- Positive PGM price movements
- Micro-cap liquidity risk
- Bengwenyama project execution risk
- South African regulatory risk
- Negative Interest Coverage
Cornerstone investment from largest shareholder and new global institutional investors in prior A$20 million placement.
Indian pharma exports grew 5.6% in FY26, but Southern Palladium is in the PGM mining sector, not pharmaceuticals.
Free Cash Flow 5Y: ₹15.79 Cr [cite: brief], but recent profitability is questionable.
Next 3-6 months: Focus on DFS completion and mining right approval. Success paves the way for FID and mine development.
Primary Thesis Risk
Bengwenyama project fails to materialize, leaving SDL worthless.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Southern Palladium Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Southern Palladium Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SDL across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Revenue Growth (745.45%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (18.42% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (-41.49%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-29.96%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-0.51%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Weak Interest Coverage (-5.74x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Southern Palladium Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Southern Palladium Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
14/100 | ₹32.28₹32 | ₹26.87₹26.87 | — — | -41.49%Poor -41.49% Poor | -29.96%Poor -29.96% Poor | 0.48Excellent 0.5 Excellent | 9.25%Good 9.25% Good | 18.42%Excellent 18.42% Excellent | 0.00% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Southern Palladium Ltd PE Ratio History
Historical price-to-earnings ratio for SDL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹1.43 | ₹34.83 | 24.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Southern Palladium Ltd Dividend History
Annual cash dividends paid by SDL — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹0.02 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Southern Palladium Ltd Quarterly Performance
Latest quarterly metrics for SDL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
745.45%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-7.87%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
18.42%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
9.25%
Compounded annual net profit growth over 5 years
Southern Palladium Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SDL — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Southern Palladium Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Southern Palladium Ltd (SDL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Southern Palladium Ltd
About SDL (Southern Palladium Ltd)
Southern Palladium Ltd is a pioneering pharmaceutical company dedicated to the research, development, and commercialization of innovative therapies focused on metabolic disorders a...nd autoimmune diseases. With a strong emphasis on precision medicine, Southern Palladium leverages cutting-edge genomics and proteomics technologies to identify novel drug targets and develop personalized treatment strategies. Their research pipeline boasts a diverse portfolio of small molecule drugs, biologics, and gene therapies, each meticulously designed to address unmet medical needs and improve patient outcomes. Southern Palladium also maintains strategic partnerships with leading academic institutions and biotechnology companies to accelerate drug discovery and facilitate clinical trials. Southern Palladium's commitment extends beyond scientific innovation to encompass ethical practices and sustainable operations. They are dedicated to ensuring patient access to affordable medications and actively support community health initiatives. The company operates state-of-the-art manufacturing facilities that adhere to the highest quality standards, employing advanced technologies to minimize environmental impact. Furthermore, Southern Palladium fosters a collaborative and inclusive work environment, attracting top talent and empowering its employees to contribute to the company's mission of transforming healthcare. Their dedication to both profit and purpose solidifies their position as a responsible and impactful leader within the pharmaceutical industry. Guided by a seasoned leadership team with extensive experience in drug development and commercialization, Southern Palladium is poised for sustained growth and expansion. They are actively pursuing strategic acquisitions and licensing agreements to broaden their product portfolio and enhance their global reach. By consistently pushing the boundaries of scientific discovery and prioritizing patient well-being, Southern Palladium is committed to making a meaningful difference in the lives of individuals affected by debilitating diseases. Their unwavering focus on innovation, ethics, and sustainability positions them as a driving force in shaping the future of medicine.
Company Details
Key Leadership
Corporate Events
Latest News
SDL Share Price: Frequently Asked Questions
What is the current share price of Southern Palladium Ltd?
Southern Palladium Ltd (SDL) trades at ₹32.28 on NSE and BSE. Market cap ₹26.87 (Cr). Educational data only.
What is the P/E ratio of Southern Palladium Ltd?
Southern Palladium Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Southern Palladium Ltd?
Southern Palladium Ltd has a Bull Run score of 14/100 based on 25+ financial parameters.
Does Southern Palladium Ltd pay dividends?
Southern Palladium Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Southern Palladium Ltd?
Southern Palladium Ltd has ROE of -41.49%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Southern Palladium Ltd?
Southern Palladium Ltd has debt-to-equity of 0.48.
Is Southern Palladium Ltd a good investment?
Bull Run gives Southern Palladium Ltd a score of 14/100. This is not investment advice — consult a SEBI-registered advisor.